BRIEF published on 04/24/2025 at 19:44, 1 year 4 months ago Mauna Kea Technologies : Résultats 2024 et Perspectives Résultats 2024 Défis Financiers Cellvizio CellTolerance Mauna Kea
BRIEF published on 04/24/2025 at 19:44, 1 year 4 months ago Mauna Kea Technologies: 2024 Results and Outlook Financial Challenges Cellvizio 2024 Results CellTolerance Mauna Kea
PRESS RELEASE published on 04/24/2025 at 19:39, 1 year 4 months ago Informations privilégiées / Communiqué sur comptes, résultats Mauna Kea Technologies annonce ses résultats financiers pour l'année 2024 et fait le point sur son activité. Progression malgré des défis avec lancement de CellTolerance et négociations en cours Résultats Financiers Croissance Négociations Mauna Kea Technologies CellTolerance
PRESS RELEASE published on 04/24/2025 at 19:39, 1 year 4 months ago Inside Information / News release on accounts, results Mauna Kea Technologies reports full year 2024 financial results and business update, discusses challenges and operational progress amidst external headwinds, strategic partnerships, and financial outlook Financial Results Strategic Partnerships Business Update Financial Outlook Mauna Kea Technologies
BRIEF published on 04/01/2025 at 09:34, 1 year 5 months ago Mauna Kea Technologies Enters Licensing Talks for Cellvizio® Licensing Agreement Financial Strategy Mauna Kea Technologies Cellvizio® Platform Therapeutic Interest
BRIEF published on 04/01/2025 at 09:34, 1 year 5 months ago Mauna Kea Technologies entame des négociations pour l'octroi d'une licence pour Cellvizio® Stratégie Financière Mauna Kea Technologies Contrat De Licence Plateforme Cellvizio® Intérêt Thérapeutique
PRESS RELEASE published on 04/01/2025 at 09:29, 1 year 5 months ago Inside Information / Other news releases Mauna Kea Technologies enters exclusive negotiations for Cellvizio® licensing agreement in important therapeutic area with major player, intensifies financing discussions with investors Investors Licensing Agreement Mauna Kea Technologies Cellvizio Therapeutic Area
PRESS RELEASE published on 04/01/2025 at 09:29, 1 year 5 months ago Informations privilégiées / Autres communiqués Mauna Kea Technologies entre en négociation exclusive pour licence Cellvizio dans large domaine thérapeutique avec acteur majeur du secteur. Discussions de licence et financement en cours Financement Négociation Exclusive Mauna Kea Technologies Cellvizio Domaine Thérapeutique
BRIEF published on 03/03/2025 at 18:00, 1 year 6 months ago ESGE Endorses Mauna Kea's Cellvizio® for Enhanced Pancreatic Cyst Diagnosis Cellvizio® Pancreatic Cysts NCLE Technology ESGE Endorsement Diagnostic Accuracy
BRIEF published on 03/03/2025 at 18:00, 1 year 6 months ago L'ESGE recommande le Cellvizio® de Mauna Kea pour un meilleur diagnostic des kystes pancréatiques Cellvizio® Kystes Pancréatiques Technologie NCLE Approbation De L'ESGE Précision Du Diagnostic
Published on 09/12/2026 at 02:35, 1 day 12 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 1 day 15 hours ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 21:25, 1 day 17 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 21 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 20 hours 56 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 1 day 7 hours ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 1 day 16 hours ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 1 day 16 hours ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 1 day 19 hours ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 2 days 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 2 days 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 2 days 19 hours ago Availability of the 2026 Interim Financial Report
